Innate immune interferon responses to Human immunodeficiency virus-1 infection

Reviews in Medical Virology

Volumn 22, Issue 4, 2012, Pages 257-266

  Hughes, Rose ^a   Towers, Greg ^a   Noursadeghi, Mahdad ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; STAT1 PROTEIN; STAT2 PROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRIPARTITE MOTIF PROTEIN 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS DNA; VIRUS RNA;

ADAPTIVE IMMUNITY; APOPTOSIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SEROCONVERSION; STEADY STATE; VIREMIA; VIRUS LOAD; VIRUS TRANSCRIPTION;

ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; INTERFERONS;

EID: 84863538200     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1708     Document Type: Review

References (87)

1. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews Immunology 2005; 5: 375-386.
2. Casrouge A, Zhang S-Y, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314: 308-312.
3. Zhang S-Y, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317: 1522-1527.
4. Pérez de Diego R, Sancho-Shimizu V, Lorenzo L, et al. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 2010; 33: 400-411.
5. Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Research & Therapy 2010; 12(Suppl 1): S1.
6. Chen W, Royer WE. Structural insights into interferon regulatory factor activation. Cellular Signalling 2010; 22: 883-887.
7. Civas A, Island M-L, Génin P, Morin P, Navarro S. Regulation of virus-induced interferon-A genes. Biochimie 2002; 84: 643-654.
8. Schlee M, Hartmann G. The chase for the RIG-I ligand--recent advances. Molecular Therapy 2010; 18: 1254-1262.
9. Loo Y-M, Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011; 34: 680-692.
10. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
11. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-1529.
12. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nature Immunology 2006; 7: 49-56.
13. Takaoka A, Taniguchi T. Cytosolic DNA recognition for triggering innate immune responses. Advanced Drug Delivery Reviews 2008; 60: 847-857.
14. Kobiyama K, Takeshita F, Jounai N, et al. Extrachromosomal histone H2B mediates innate antiviral immune responses induced by intracellular double-stranded DNA. Journal of Virology 2010; 84: 822-832.
15. Yang P, An H, Liu X, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nature Immunology 2010; 11: 487-494.
16. Unterholzner L, Keating SE, Baran M, et al. IFI16 is an innate immune sensor for intracellular DNA. Nature Immunology 2010; 11: 997-1004.
17. Fernandes-Alnemri T, Yu J-W, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458: 509-513.
18. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nature Immunology 2009; 10: 1065-1072.
19. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cellular Microbiology 2006; 8: 907-922.
20. Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. Journal of Interferon and Cytokine Research 2006; 26: 373-379.
21. DeFilippis VR, Robinson B, Keck TM, Hansen SG, Nelson JA, Früh KJ. Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection. Journal of Virology 2006; 80: 1032-1037.
22. DeFilippis V, Früh K. Rhesus cytomegalovirus particles prevent activation of interferon regulatory factor 3. Journal of Virology 2005; 79: 6419-6431.
23. Zhu H, Cong JP, Shenk T. Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of interferon-responsive RNAs. Proceedings of the National Academy of Sciences of the United States of America 1997; 94: 13985-13990.
24. Boyle KA, Pietropaolo RL, Compton T. Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathway. Molecular and Cellular Biology 1999; 19: 3607-3613.
25. Towers GJ. Control of viral infectivity by tripartite motif proteins. Human Gene Therapy 2005; 16: 1125-1132.
26. Towers GJ. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007; 4: 40.
27. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427: 848-853.
28. Huthoff H, Towers GJ. Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends in Microbiology 2008; 16: 612-619.
29. Ylinen LMJ, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ. Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. Journal of Virology 2005; 79: 11580-11587.
30. Kajaste-Rudnitski A, Marelli SS, Pultrone C, et al. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. Journal of Virology 2011; 85: 5183-5196.
31. Neil SJD, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-430.
32. Bishop KN, Verma M, Kim E-Y, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathogens 2008; 4: e1000231.
33. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
34. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. Journal of Leukocyte Biology 2002; 71: 565-581.
35. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. Journal of Virology 2009; 83: 3719-3733.
36. Francis ML, Fan XS, Meltzer MS. Loss ability to produce IFN-alpha in response to HIV-1 as monocytes differentiate into macrophages. Induction through a mechanism independent of double-stranded RNA. Journal of Immunology 1996; 156: 2481-2487.
37. Fonteneau J-F, Larsson M, Beignon A-S, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. Journal of Virology 2004; 78: 5223-5232.
38. Yonezawa A, Morita R, Takaori-Kondo A, et al. Natural alpha interferon-producing cells respond to human immunodeficiency virus type 1 with alpha interferon production and maturation into dendritic cells. Journal of Virology 2003; 77: 3777-3784.
39. Liu Y-J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annual Review of Immunology 2005; 23: 275-306.
40. Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. Journal of Internal Medicine 2009; 265:43-57.
41. Colonna M, Trinchieri G, Liu Y-J. Plasmacytoid dendritic cells in immunity. Nature Immunology 2004; 5: 1219-1226.
42. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. The Journal of Experimental Medicine 2001; 194: 863-869.
43. Lepelley A, Louis S, Sourisseau M, et al. Innate sensing of HIV-infected cells. PLoS Pathogens 2011; 7: e1001284.
44. Beignon A-S, McKenna K, Skoberne M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. The Journal of Clinical Investigation 2005; 115: 3265-3275.
45. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annual Review of Medicine 2011; 62: 127-139.
46. Jiang W, Lederman MM, Salkowitz JR, Rodriguez B, Harding CV, Sieg SF. Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production. Journal of Virology 2005; 79: 4109-4119.
47. Feldman SB, Milone MC, Kloser P, Fitzgerald-Bocarsly P. Functional deficiencies in two distinct interferon alpha-producing cell populations in peripheral blood mononuclear cells from human immunodeficiency virus seropositive patients. Journal of Leukocyte Biology 1995; 57: 214-220.
48. Soumelis V, Scott I, Gheyas F, et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001; 98: 906-912.
49. Chehimi J, Campbell DE, Azzoni L, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. Journal of Immunology 2002; 168: 4796-4801.
50. Dillon SM, Robertson KB, Pan SC, et al. Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 2008; 48: 1-12.
51. Lehmann C, Lafferty M, Garzino-Demo A, et al. Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients. PLoS One 2010;5:e11110.
52. Tilton JC, Manion MM, Luskin MR, et al. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. Journal of Virology 2008; 82: 3997-4006.
53. Rotger M, Dang KK, Fellay J, et al. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathogens 2010; 6: e1000781.
54. Hyrcza MD, Kovacs C, Loutfy M, et al. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. Journal of Virology 2007; 81: 3477-3486.
55. Moir S, Malaspina A, Pickeral OK, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. Journal of Experimental Medicine 2004; 200: 587-599.
56. Singh R, Gaiha G, Werner L, et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. Journal of Virology 2011; 85: 208-216.
57. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Research and Human Retroviruses 2006; 22: 757-762.
58. Biglino A, Sinicco A, Forno B, et al. Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. Clinical Immunology and Immunopathology 1996; 78: 61-69.
59. Sinicco A, Biglino A, Sciandra M, et al. Cytokine network and acute primary HIV-1 infection. AIDS 1993; 7: 1167-1172.
60. Herbeuval J-P, Shearer GM. HIV-1 immunopathogenesis: how good interferon turns bad. Clinical Immunology 2007; 123: 121-128.
61. Hardy AW, Graham DR, Shearer GM, Herbeuval J-P. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 17453-17458.
62. Stary G, Klein I, Kohlhofer S, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood 2009; 114: 3854-3863.
63. Chehimi J, Papasavvas E, Tomescu C, et al. Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand. Journal of Virology 2010; 84: 2762-2773.
64. Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. Journal of Infectious Diseases 2003; 188: 1498-1507.
65. Tavel JA, Huang C-Y, Shen J, et al. Interferon-alpha produces significant decreases in HIV load. Journal of Interferon and Cytokine Research 2010; 30: 461-464.
66. Dianzani F, Rozera G, Abbate I, et al. Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. Journal of Interferon and Cytokine Research 2008; 28: 1-3.
67. Keele BF, Estes JD. Barriers to mucosal transmission of immunodeficiency viruses. Blood 2011; 118: 839-846.
68. Noursadeghi M, Katz DR, Miller RF. HIV-1 infection of mononuclear phagocytic cells: the case for bacterial innate immune deficiency in AIDS. Lancet Infectious Diseases 2006; 6: 794-804.
69. Kuroishi A, Bozek K, Shioda T, Nakayama EE. A single amino acid substitution of the human immunodeficiency virus type 1 capsid protein affects viral sensitivity to TRIM5 alpha. Retrovirology 2010; 7: 58.
70. Owens CM, Song B, Perron MJ, Yang PC, Stremlau M, Sodroski J. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. Journal of Virology 2004; 78: 5423-5437.
71. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Medicine 2003; 9: 1404-1407.
72. Goffinet C, Homann S, Ambiel I, et al. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. Journal of Virology 2010; 84: 4089-4094.
73. Gupta RK, Towers GJ. A tail of Tetherin: how pandemic HIV-1 conquered the world. Cell Host & Microbe 2009; 6: 393-395.
74. Tsang J, Chain BM, Miller RF, et al. HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation. AIDS 2009; 23: 2255-2263.
75. Goujon C, Malim MH. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. Journal of Virology 2010; 84: 9254-9266.
76. Trapp S, Derby NR, Singer R, et al. Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. Journal of Virology 2009; 83: 884-895.
77. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nature Immunology 2010; 11: 1005-1013.
78. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134: 587-598.
79. Doitsh G, Cavrois M, Lassen KG, et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010; 143: 789-801.
80. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-657.
81. Hrecka K, Hao C, Gierszewska M, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658-661.
82. Masso M. DC-SIGN points the way to a novel mechanism for HIV-1 transmission. MedGenMed 2003; 5: 2.
83. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010; 467: 214-217.
84. Harman AN, Kraus M, Bye CR, et al. HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase. Blood 2009;114:85-94.
85. Harman AN, Lai J, Turville S, et al. HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood 2011; 118: 298-308.
86. Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, Pitha PM. HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 2008; 373: 85-97.
87. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. Journal of Virology 2009; 83: 10395-10405.